The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

STOCKHOLM — Vitamin D deficiency is strongly associated with lower rates of progression-free survival (PFS) and overall survival (OS) in patients with Hodgkin lymphoma, independently of key factors ...

Hodgkin lymphoma (HL) is a treatable cancer with an incidence peak in adolescent and young adult years. Treatment strategies have been developed to balance the intensity of therapy needed to maintain ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

Patients with lymphoma have better odds of survival now than they did 20 years ago, according to new research. The data also help explain which types of cancer continue to be the most challenging.

Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a new study. Combining two different immunotherapy treatments could dramatically improve ...

The authors performed a retrospective analysis of 126,501 patients with lymphoma from the National Cancer Data Base. They built a multivariate model to determine the risk of mortality based on ...

Conditional survival is the probability that a patient with a given disease will survive an additional number of years based on the fact that he or she has already survived a specific number of years.

Autoimmune diseases (AIs) are associated with elevated risk for Hodgkin's lymphoma (HL); however, information on the interplay of AIs and HL on survival is sparse. Patients with HL have an overall ...

The Voice features host Gloria Burns in a meaningful conversation with Roxie Soto from the Leukemia & Lymphoma Society (LLS) to highlight the organization’s mission, patient support programs, ...